136 related articles for article (PubMed ID: 32015512)
1. Diagnostic accuracy of circulating-free DNA for the determination of MYCN amplification status in advanced-stage neuroblastoma: a systematic review and meta-analysis.
Trigg RM; Turner SD; Shaw JA; Jahangiri L
Br J Cancer; 2020 Mar; 122(7):1077-1084. PubMed ID: 32015512
[TBL] [Abstract][Full Text] [Related]
2. Serum-Based Quantification of MYCN Gene Amplification in Young Patients with Neuroblastoma: Potential Utility as a Surrogate Biomarker for Neuroblastoma.
Yagyu S; Iehara T; Tanaka S; Gotoh T; Misawa-Furihata A; Sugimoto T; London WB; Hogarty MD; Teramukai S; Nakagawara A; Hiyama E; Maris JM; Hosoi H
PLoS One; 2016; 11(8):e0161039. PubMed ID: 27513929
[TBL] [Abstract][Full Text] [Related]
3. Detection of MYCN Amplification in Serum DNA Using Conventional Polymerase Chain Reaction.
Ma Y; Lee JW; Park SJ; Yi ES; Choi YB; Yoo KH; Sung KW; Koo HH
J Korean Med Sci; 2016 Sep; 31(9):1392-6. PubMed ID: 27510381
[TBL] [Abstract][Full Text] [Related]
4. A prospective evaluation of liquid biopsy for detecting MYCN amplification in neuroblastoma patients.
Iehara T; Yagyu S; Gotoh T; Ouchi K; Yoshida H; Miyachi M; Kikuchi K; Sugimoto T; Hosoi H
Jpn J Clin Oncol; 2019 Aug; 49(8):743-748. PubMed ID: 31053863
[TBL] [Abstract][Full Text] [Related]
5. Prediction of MYCN amplification in neuroblastoma using serum DNA and real-time quantitative polymerase chain reaction.
Gotoh T; Hosoi H; Iehara T; Kuwahara Y; Osone S; Tsuchiya K; Ohira M; Nakagawara A; Kuroda H; Sugimoto T
J Clin Oncol; 2005 Aug; 23(22):5205-10. PubMed ID: 16051962
[TBL] [Abstract][Full Text] [Related]
6. Identification of patient subgroups with markedly disparate rates of MYCN amplification in neuroblastoma: A report from the International Neuroblastoma Risk Group project.
Thompson D; Vo KT; London WB; Fischer M; Ambros PF; Nakagawara A; Brodeur GM; Matthay KK; DuBois SG
Cancer; 2016 Mar; 122(6):935-45. PubMed ID: 26709890
[TBL] [Abstract][Full Text] [Related]
7. Quantitative assessment of copy number alterations by liquid biopsy for neuroblastoma.
Shirai R; Osumi T; Sato-Otsubo A; Nakabayashi K; Ishiwata K; Yamada Y; Yoshida M; Yoshida K; Shioda Y; Kiyotani C; Terashima K; Tomizawa D; Takasugi N; Takita J; Miyazaki O; Kiyokawa N; Yoneda A; Kanamori Y; Hishiki T; Matsumoto K; Hata K; Yoshioka T; Kato M
Genes Chromosomes Cancer; 2022 Nov; 61(11):662-669. PubMed ID: 35655408
[TBL] [Abstract][Full Text] [Related]
8. Association of heterogeneous MYCN amplification with clinical features, biological characteristics and outcomes in neuroblastoma: A report from the Children's Oncology Group.
Campbell K; Naranjo A; Hibbitts E; Gastier-Foster JM; Bagatell R; Irwin MS; Shimada H; Hogarty M; Park JR; DuBois SG
Eur J Cancer; 2020 Jul; 133():112-119. PubMed ID: 32492633
[TBL] [Abstract][Full Text] [Related]
9. Plasma circulating cell-free MYCN gene: A noninvasive and prominent recurrence monitoring indicator of neuroblastoma.
Liang Y; Liu Y; Zhang P; Zhang M; Du B; Cheng W; Yu Z; Li L; Wang H; Hou G; Zhang X; Zhang W
Cancer Rep (Hoboken); 2023 Feb; 6(2):e1688. PubMed ID: 35892165
[TBL] [Abstract][Full Text] [Related]
10. Implementation of the plasma MYCN/NAGK ratio to detect MYCN amplification in patients with neuroblastoma.
Su Y; Wang L; Zhao Q; Yue Z; Zhao W; Wang X; Duan C; Jin M; Zhang D; Chen S; Yin J; Qiu L; Cheng X; Xu Z; Ma X
Mol Oncol; 2020 Nov; 14(11):2884-2893. PubMed ID: 32896084
[TBL] [Abstract][Full Text] [Related]
11. Heterogeneous MYCN amplification in neuroblastoma: a SIOP Europe Neuroblastoma Study.
Berbegall AP; Bogen D; Pötschger U; Beiske K; Bown N; Combaret V; Defferrari R; Jeison M; Mazzocco K; Varesio L; Vicha A; Ash S; Castel V; Coze C; Ladenstein R; Owens C; Papadakis V; Ruud E; Amann G; Sementa AR; Navarro S; Ambros PF; Noguera R; Ambros IM
Br J Cancer; 2018 May; 118(11):1502-1512. PubMed ID: 29755120
[TBL] [Abstract][Full Text] [Related]
12. Circulating methylated-DCR2 gene in serum as an indicator of prognosis and therapeutic efficacy in patients with MYCN nonamplified neuroblastoma.
Yagyu S; Gotoh T; Iehara T; Miyachi M; Katsumi Y; Tsubai-Shimizu S; Kikuchi K; Tamura S; Tsuchiya K; Imamura T; Misawa-Furihata A; Sugimoto T; Sawada T; Hosoi H
Clin Cancer Res; 2008 Nov; 14(21):7011-9. PubMed ID: 18980997
[TBL] [Abstract][Full Text] [Related]
13. Association of MYCN copy number with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology Group.
Campbell K; Gastier-Foster JM; Mann M; Naranjo AH; Van Ryn C; Bagatell R; Matthay KK; London WB; Irwin MS; Shimada H; Granger MM; Hogarty MD; Park JR; DuBois SG
Cancer; 2017 Nov; 123(21):4224-4235. PubMed ID: 28696504
[TBL] [Abstract][Full Text] [Related]
14. Influence of neuroblastoma stage on serum-based detection of MYCN amplification.
Combaret V; Hogarty MD; London WB; McGrady P; Iacono I; Brejon S; Swerts K; Noguera R; Gross N; Rousseau R; Puisieux A
Pediatr Blood Cancer; 2009 Sep; 53(3):329-31. PubMed ID: 19301388
[TBL] [Abstract][Full Text] [Related]
15. A MYCN-independent mechanism mediating secretome reprogramming and metastasis in
Zhang HF; Delaidelli A; Javed S; Turgu B; Morrison T; Hughes CS; Yang X; Pachva M; Lizardo MM; Singh G; Hoffmann J; Huang YZ; Patel K; Shraim R; Kung SHY; Morin GB; Aparicio S; Martinez D; Maris JM; Bosse KR; Williams KC; Sorensen PH
Sci Adv; 2023 Aug; 9(34):eadg6693. PubMed ID: 37611092
[No Abstract] [Full Text] [Related]
16. Cell-free DNA Oncogene Copy Number as a Surrogate Molecular Biomarker in ALK/MYCN-coamplified Neuroblastoma.
Kobayashi K; Mizuta S; Yamane N; Hamabata T; Maihara T; Usami I; Heike T
J Pediatr Hematol Oncol; 2021 Mar; 43(2):e165-e168. PubMed ID: 32032241
[TBL] [Abstract][Full Text] [Related]
17. MYCN gene amplification is a powerful prognostic factor even in infantile neuroblastoma detected by mass screening.
Iehara T; Hosoi H; Akazawa K; Matsumoto Y; Yamamoto K; Suita S; Tajiri T; Kusafuka T; Hiyama E; Kaneko M; Sasaki F; Sugimoto T; Sawada T
Br J Cancer; 2006 May; 94(10):1510-5. PubMed ID: 16670717
[TBL] [Abstract][Full Text] [Related]
18. [Study on MYCN gene amplification and CD44 expression in neuroblastoma].
Hu HL; He LJ
Zhonghua Bing Li Xue Za Zhi; 2004 Aug; 33(4):332-6. PubMed ID: 15363318
[TBL] [Abstract][Full Text] [Related]
19. Multiplexed Quantification of Four Neuroblastoma DNA Targets in a Single Droplet Digital PCR Reaction.
Peitz C; Sprüssel A; Linke RB; Astrahantseff K; Grimaldi M; Schmelz K; Toedling J; Schulte JH; Fischer M; Messerschmidt C; Beule D; Keilholz U; Eggert A; Deubzer HE; Lodrini M
J Mol Diagn; 2020 Nov; 22(11):1309-1323. PubMed ID: 32858250
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA-149 is associated with clinical outcome in human neuroblastoma and modulates cancer cell proliferation through Rap1 independent of MYCN amplification.
Xu Y; Chen X; Lin L; Chen H; Yu S; Li D
Biochimie; 2017 Aug; 139():1-8. PubMed ID: 28456710
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
